Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 15;327(11):1085-1087.
doi: 10.1001/jama.2022.1393.

Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19

Jennifer L Alejo  1 , Jonathan Mitchell  1 , Amy Chang  1 , Teresa P Y Chiang  1 , Allan B Massie  1 , Dorry L Segev  1 , Martin A Makary  1
Affiliations

Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19

Jennifer L Alejo et al. JAMA. .

Abstract

This study uses serologic testing to characterize natural immunity and the long-term durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19 infection.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Alejo reported receiving a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (T32DK007713). Dr Mitchell reported receiving a grant from the American Society of Transplant Surgeons Jon Fryer Resident Scientist Scholarship. Dr Chang reported receiving a grant from the NIDDK (T32DK007732). Dr Massie reported receiving grants from the NIDDK. Dr Segev reported receiving consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, AstraZeneca, and Regeneron and receiving grants from the NIDDK and the National Institute of Allergy and Infectious Diseases. No other disclosures were reported.

Figures

Figure.
Figure.. Anti-Spike RBD Levels by Time Since COVID-19 Diagnosis
Anti–receptor-binding domain (RBD) levels did not differ by months since COVID-19 diagnosis (0.8% increase [95% CI, –2.4% to 4.2%] per month; P = .62). Data markers indicate individual anti-RBD titers; solid orange curve with shaded area, linear regression with 95% confidence range.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. USAFacts . Secondary US coronavirus vaccine tracker 2021. Accessed December 28, 2021. https://usafacts.org/issues/coronavirus/
    1. Jones JM, Stone M, Sulaeman H, et al. . Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021. JAMA. 2021;326(14):1400-1409. doi:10.1001/jama.2021.15161 - DOI - PMC - PubMed
    1. Liu W, Russell RM, Bibollet-Ruche F, et al. . Predictors of nonseroconversion after SARS-CoV-2 infection. Emerg Infect Dis. 2021;27(9):2454-2458. doi:10.3201/eid2709.211042 - DOI - PMC - PubMed
    1. Gilbert PB, Montefiori DC, McDermott AB, et al. ; Immune Assays Team; Moderna Inc Team; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team; US Government (USG)/CoVPN Biostatistics Team . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50. doi:10.1126/science.abm3425 - DOI - PMC - PubMed
    1. Israel A, Shenhar Y, Green I, et al. . Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines (Basel). 2021;10(1):64. doi:10.3390/vaccines10010064 - DOI - PMC - PubMed

Publication types

Substances